ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1307

Combination of Hypertension and Preexisting Cardiovascular Disease and Mortality in Patients on Continuous Ambulatory Peritoneal Dialysis

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Wu, Xianfeng, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China
  • Wang, Niansong, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China
  • Wu, Junnan, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China
Background

Little is known about whether combination of hypertension and pre-existing cardiovascular disease (CVD) is more strongly associated with outcomes compared with either comorbidity alone in patients on continuous ambulatory peritoneal dialysis (CAPD).

Methods

We conducted a retrospective study of 3073 incident Chinese patients on CAPD from five dialysis centers between January 1, 2005 and December 31, 2018 in a real-world setting. All patients were divided four groups: group 1 (patients without either hypertension or pre-existing CVD); group 2 (patients with only hypertension); group 3 (patients with only pre-existing CVD); group 4 (patients with both hypertension and pre-existing CVD). The association between interesting comorbidities and mortality was analyzed using Cox regression models.

Results

Over a median of 33.7 months of follow-up, 581 (18.6%) patients died, with 286 (9.3%) CVD mortality. The incidence of all-cause mortality was 32.2, 56.1, 74.4, and 131.0/1000 patient-years, and the incidence of CVD mortality was 15.0, 28.2, 34.7, and 69.6/1000 patient-years in group 1, 2, 3, and 4, respectively. Cumulative survival and CVD mortality-free survival were lowest in those with both hypertension and pre-existing CVD (Figure 1). After adjusting for the demographic characteristics and laboratory parameters, group 4, 3, and 2 had 3.07 (95% CI 2.23 to 4.22), 2.05 (95% CI 1.11 to 3.80), and 1.38 (95% CI 1.08 to 1.77) of hazard ratios for all-cause mortality, and 3.20 (95% CI 2.04 to 5.03), 2.09 (95% CI 0.85 to 5.15), and 1.56 (95% CI 1.09 to 2.23) of hazard ratios for CVD mortality, respectively, compared to the group 1.

Conclusion

Combination of hypertension and pre-existing CVD was more strongly associated with mortality compared to either comorbidity alone in CAPD patients.